Results 251 to 260 of about 221,455 (333)

INTRAVITREOUS METHOTREXATE AND RITUXIMAB FOR BILATERAL DIFFUSE UVEAL MELANOCYTIC PROLIFERATION. [PDF]

Retin Cases Brief Rep
Francis JH, Canestraro J, Abramson DH.
europepmc   +1 more source

A phase IIa study of the anti‐PD‐L1 antibody avelumab in relapsed/refractory PTCL: The AVAIL‐T trial

British Journal of Haematology, EarlyView.
The AVAIL‐T study, the first evaluation of programmed death ligand 1 (PD‐L1) blockade in relapsed/refractory peripheral T‐cell lymphomas (PTCL), demonstrated limited single agent activity with durable responses seen in a minority. Circulating tumour DNA revealed distinct mutational dynamics and mass cytometry identified perturbed T‐cell subsets ...
Matthew J. Ahearne, Matthew A. Timmins, Charlotte Gaskell, Aimee Jackson, Clare Morland, Sonia Fox, Louise Hopkins, Nadia Nawaz, Susann Lehmann, Marc Wadsley, Caroline Cowley, Jacqueline Shaw, Naeem Khan, Nagesh Kalakonda, Christopher Trethewey, Ram Malladi, Paul Fields, Dima El Sharkawi, Michael Quinn, Nimish Shah, Andrew Davies, Kim Linton, Pam McKay, Rod Johnson, Simon D. Wagner, David Lewis, Graham P. Collins, Christopher P. Fox, Kate Cwynarski   +28 more
wiley   +1 more source

Staged multi-target therapy for <i>anti</i>-MDA5-positive dermatomyositis-associated rapidly progressive interstitial lung disease: a case report. [PDF]

Respir Med Case Rep
Zhang L, Jiao M, Hou Y, Jie Y, Mo S, Chen W, Xue Q, Qiao Y.   +7 more
europepmc   +1 more source

Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia—Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups

British Journal of Haematology, EarlyView.
Summary Most patients treated for chronic lymphocytic leukaemia (CLL) fail to achieve measurable residual disease (MRD) negativity. The role of maintenance with the immunomodulatory drug lenalidomide in these patients is unclear. A randomised multicentre phase III trial (ACTRN12610000060044) was conducted in Australia and France to assess the effect of
Thérèse Aurran‐Schleinitz, Rémi Letestu, Mary Sartor, Stephen Mulligan, Marie C. Béné, Gavin Cull, Dennis Carney, William Renwick, Andrew Grigg, Cecily Forsyth, Gregory Hapgood, Emma Verner, Rosemary Harrup, Pauline Warburton, Kylie Mason, Richard Eek, Wojciech Janowski, Jean Pierre Vilque, Maya Latimer, Laurent Voillat, Sophie De Guibert, Bernard Drenou, Robert Blum, Caroline Dartigeas, Lachlan Hayes, Nicolas Daguindau, Mourad Tiab, Véronique Leblond, Andrew Shearer, Masa Lasica, Pierre Morel, Bohrane Slama, Anne Banos, Annie Brion, Emmanuelle Ferrant, Jessica Michel, Cécile Tomowiak, Edward Morris, Hanlon Sia, Kelly Kratzing, Belinda E. Butcher, Abdelmalek Dahmani, Stephen Robert Larsen, Piers Blombery, Florence Cymbalista, David J. Gottlieb   +45 more
wiley   +1 more source

A case report of sequential efgartigimod and rituximab treatment for tSNMG. [PDF]

Front Immunol
Xie H, Pan TT, Zhang L.
europepmc   +1 more source

Voltage-dependent anion channel 2 (VDAC2) drives rituximab resistance via inhibiting ferroptosis in diffuse large B cell lymphoma. [PDF]

Chin Med J (Engl)
Li Q, Xia J, Ma N, Li X, Liu B, Huang D, Duan Y, Li J, Zhou S, Xiong J, Gao L, Zhang X, Rao J.   +12 more
europepmc   +1 more source

Ibrutinib and standard immunochemotherapy in younger, high‐risk patients with diffuse large B‐cell lymphoma: A phase II study of GLA

British Journal of Haematology, EarlyView.
Summary Younger patients with high‐risk diffuse large B‐cell lymphoma (DLBCL) frequently have unfavourable outcomes. We conducted a prospective phase II study evaluating ibrutinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R‐CHOEP+I) in patients aged 18–60 years with DLBCL and age‐adjusted international prognostic index ≥2.
Evgenii Shumilov, Marita Ziepert, Birte Friedrichs, Susanne Ghandili, Kai Wille, Bertram Glass, Maike Nickelsen, Peter Borchmann, Andreas Viardot, Andrea Kerkhoff, Philipp Berning, Sebastian Böttcher, Stefan Wirths, Tobias Kewitz, Mathias Hänel, Judith Dierlamm, Andreas Rosenwald, Bettina Altmann, Georg Lenz, Norbert Schmitz   +19 more
wiley   +1 more source

Whole‐genome and transcriptome analysis in relapsed/refractory non‐Hodgkin lymphoma: Results from a multicentre precision oncology cohort

British Journal of Haematology, EarlyView.
Summary Comprehensive genome and transcriptome profiling can inform the diagnosis, prognosis and management of relapsed/refractory (R/R) solid malignancies, yet its integration into clinical care has lagged despite strong biological rationale. We evaluated the clinical utility of whole genome and transcriptome analysis (WGTA) in 65 patients (37 ...
Kathleen Wee, Eric J. Zhao, Cassidy Clemente‐Jones, Rebecca J. Deyell, Shahrad R. Rassekh, Anita Villani, Rosemarie Venier, Daniel Sinnett, Sylvie Langlois, Thai Hoa Tran, Thomas Sontag, Stephanie Grover, Scott Davidson, Nisha Kanwar, Winnie Lo, Erin Pleasance, Laura Williamson, Yaoqing Shen, Alina S. Gerrie, Kerry J. Savage, Laurie H. Sehn, Christopher P. Venner, Marco A. Marra, Janessa Laskin, Diego Villa   +24 more
wiley   +1 more source

Adult-Onset IgA Vasculitis With Concurrent Gastrointestinal and Possible Coronary Involvement. [PDF]

Cureus
Suleman M, Chauhan S, Chan A.
europepmc   +1 more source

The immunological landscape of the area postrema in neuromyelitis optica spectrum disorders

Brain Pathology, EarlyView.
Aquaporin‐4 antibody‐positive neuromyelitis spectrum disorder is characterized by large tissue destructive lesions in medulla, spinal cord, and optic nerves, with only partial recovery from clinical symptoms, and by lesions with very little tissue destruction and mostly complete recovery from clinical symptoms, as seen in the area postrema ...
Qian Yu, Yoshiki Takai, Naoya Yamazaki, Sarah Brandl, Katharina M. Mair, Thibault Bouderlique, Maria Eleni Kastriti, Igor Adameyko, Romana Höftberger, Markus Reindl, Jan Bauer, Monika Bradl   +11 more
wiley   +1 more source